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Homocysteine and methionine metabolism in ESRD: A stable mens. Folic acid-containing regimens have been shown
isotope study. to be able to lower plasma homocysteine concentration
Background. Hyperhomocysteinemia has a high prevalence in ESRD patients [3–9]. These studies have also demon-in the end-stage renal disease (ESRD) population, which may
strated that normalization of plasma homocysteine oc-contribute to the high cardiovascular risk in these patients.
curs in only a small proportion of patients, an observationThe cause of hyperhomocysteinemia in renal failure is un-
known, and therapies have not been able to normalize plasma that is currently unexplained. To develop more effective
homocysteine levels. Insight into methionine-homocysteine therapies, further insight into the pathogenic mechanism
metabolism in ESRD is therefore necessary. of hyperhomocysteinemia in renal failure is essential.Methods. Using a primed, continuous infusion of [2H3- Homocysteine is the transmethylation product of themethyl-1-13C]methionine, we measured whole body rates of
essential sulfur-containing amino acid methionine [10].methionine and homocysteine metabolism in the fasting state
in four hyperhomocysteinemic hemodialysis patients and six S-adenosylmethionine (AdoMet) and S-adenosylhomo-
healthy control subjects. cysteine (AdoHcy) are intermediates in this pathway.
Results. Remethylation of homocysteine was significantly Homocysteine can be either remethylated to methioninedecreased in the hemodialysis patients: 2.6 6 0.2 (sem) vs. 3.8 6
or degraded through the transsulfuration pathway. There0.3 mmol · kg21 · hr21 in the control subjects (P 5 0.03), whereas
are two different remethylation pathways. The first re-transsulfuration was not 2.5 6 0.3 vs. 3.0 6 0.1 mmol · kg21 ·
hr21 (P 5 0.11). The transmethylation rate was proportionally quires 5-methyltetrahydrofolate as methyl donor and re-
and significantly lower in the ESRD patients as compared with duced cobalamin as a cofactor. 5-Methyltetrahydrofolate
controls: 5.2 6 0.4 vs. 6.8 6 0.3 mmol · kg21 · hr21 (P 5 0.02). is generated by a reaction catalyzed by 5,10-methylene-Methionine fluxes to and from body protein were similar.
tetrahydrofolate reductase (MTHFR), of which a com-Conclusions. The conversion of homocysteine to methio-
mon, thermolabile, and less active variant resulting fromnine is substantially (approximately 30%) decreased in hemo-
dialysis patients, whereas transsulfuration is not. Decreased a cytidine to thymidine point mutation at position 677 has
remethylation may explain hyperhomocysteinemia in ESRD. been described [11]. The second remethylation reaction
This stable isotope technique is applicable for developing new uses betaine as methyl donor. In the transsulfurationand effective homocysteine-lowering treatment regimens in
pathway, homocysteine condenses with serine to formESRD based on pathophysiological mechanisms.
cystathionine, which is subsequently cleaved into cyste-
ine and a-ketobutyrate. Both reactions are irreversible
and require the active form of vitamin B6, pyridoxalHyperhomocysteinemia is an independent cardiovas-
59-phosphate, as a cofactor.cular risk factor in end-stage renal disease (ESRD) [1]
Possible pathophysiological mechanisms of hyperho-with a prevalence as high as 85 to 100% [2, 3]. Many
mocysteinemia in renal failure focus on a decreaseddialysis patients are therefore at risk, necessitating the
homocysteine metabolism in or outside of the kidney.development and testing of adequate treatment regi-
Patients with chronic renal failure exhibit a substantial
decrease in plasma homocysteine clearance after oral
homocysteine loading [12]. The loss of urinary homocys-Key words: hemodialysis, breath, cardiovascular risk, hyperhomocys-
teinemia, renal failure. teine excretion is an unlikely mechanism, as this is nor-
mally negligible [13, 14]. An impaired homocysteineReceived for publication November 13, 1998
transsulfuration in the kidney has been postulated by inand in revised form March 9, 1999
Accepted for publication March 31, 1999 vitro observations that homocysteine is transsulfurated
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Table 1. Baseline characteristics of the study subjects
Age Body wt tHcy Folate B12 B6
Subject Sex years kg MTHFR lmol/liter nmol/liter pmol/liter nmol/liter
ESRD
#1, APKD M 69 81 CT 43.6 17.8 182 11
#2, HUS F 51 82 CC 63.2 17.4 403 93
#3, CGN F 31 61 CT 49.4 14.3 193 32
#4, CGN F 25 54 CC 57.0 14.2 201 16
Mean 6 sem 44610 7067 53.364.3 15.9 61.0 245 653 38 619
Control
#1 M 41 68 CC 7.0 16.1 290 44
#2 M 20 70 CT 5.6 28.7 368 81
#3 M 22 78 TT 14.1 11.7 186 35
#4 M 50 84 CT 7.7 14.1 332 58
#5 F 21 75 CC 10.2 12.3 124 70
#6 F 53 63 CT 12.0 23.0 197 27
Mean 6 sem 3566 7363 9.461.3 17.762.8 250 639 53 69
P 0.42 0.62 ,0.01 0.64 0.94 0.45
Abbreviations are: Body wt, body weight; MTHFR, methylenetetrahydrofolate reductase; CC, homozygous wild-type; CT, heterozygous; TT, homozygous mutant;
tHcy, plasma total homocysteine; APKD, adult polycystic kidney disease; HUS, hemolytic uremic syndrome; CGN, chronic glomerulonephritis.
there is a net uptake of homocysteine in the normal rat described by Storch et al [18]. Because of the presence
of four additional neutrons, this stable isotope has akidney [16]. However, we have recently shown that the
kidney does not extract homocysteine from the circula- molecular weight of m 1 4 relative to natural methionine
(m). The metabolism of methionine and homocysteinetion in fasting humans with normal renal function [17].
To understand the pathophysiology of hyperhomocys- occurs in the intracellular compartment. We assumed
that the intracellular and intravascular compartments areteinemia in ESRD, it is necessary to quantitatively assess
methionine transmethylation and homocysteine remeth- in rapid and complete isotopic equilibrium. In steady-
ylation and transsulfuration in ESRD patients. In this state conditions, the appearance and disappearance of
study, we used a stable isotope tracer technique to deter- whole body methionine can be determined [18, 19].
mine whole body rates of use of methionine and homo- Methionine is the only known precursor of homocysteine
cysteine in ESRD patients and in healthy control sub- in humans, and when no dietary intake of methionine
jects. takes place, remethylation of homocysteine and endoge-
nous protein breakdown are the only sources of methio-
nine. The 2H3-methyl label is removed from methionineMETHODS
during transmethylation and thus [2H3-methyl-1-13C]methi-
Subjects onine is converted to [1-13C]homocysteine. Homocys-
Six healthy control subjects (mean age 35 years, four teine can be recycled to methionine by accepting a
males) and four ESRD patients (mean age 44 years, one methyl group from either betaine or 5-methyltetrahy-
male) on maintenance hemodialysis treatment partici- drofolate. Enrichment by 2H3 of the methyl groups of
pated in the study. Patients were on chronic standard these two donors is negligible in tracer studies of short
bicarbonate hemodialysis three times per week. The duration [18]. Remethylation results in the generation of
mean time on dialysis was 36 months (range 4 to 82). m 1 1 methionine, because the 13C atom of the carboxyl
All patients received one multivitamin tablet per day moiety of homocysteine remains intact. In contrast, dur-
containing 2 mg pyridoxine, but no folic acid or vitamin ing transsulfuration, the carboxyl moiety of [1-13C]homo-
B12. The control subjects did not use medication or vita- cysteine loses its 13C atom. When a-ketobutyrate is oxi-
min supplements. Subjects’ characteristics are shown in dized in the Krebs cycle, the label appears as 13CO2 in
Table 1. breath air after passage through the body bicarbonate
The study protocol was approved by the ethics com- pool. The m 1 4 methionine tracer is diluted by methio-
mittee of the University Hospital Vrije Universiteit, and nine entering the pool via the diet, from homocysteine
all participants gave their written informed consent. remethylation, and by free methionine entering from
protein breakdown in the tissues. In steady state, the
Experimental design rate of appearance of methionine from these sources
equals the rate of disappearance (that is, protein synthe-We used doubly labeled methionine (L-[2H3-methyl-
1-13C]methionine) as a tracer, according to the method sis and transmethylation).
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Yorba Linda, CA, USA). Internal calibration for carbon
dioxide and volume were conducted before each infu-
sion. Gas volumes were automatically corrected for tem-
perature and air pressure.
Tracer administration
L-[2H3-methyl-1-13C]methionine (isotopic purity-dila-
beled methionine 95 mole percentage excess, (MPE);
1-13C, 99 atom percentage (AP); 2H3-methyl, 99 AP 2H1;
Mass Trace, Woburn, MA, USA) was dissolved in sterile
saline solution, filtered twice (through 1.2 and 0.2 mm
membrane filters), and used within 24 hours. NaH13CO3
Fig. 1. Study protocol. Individuals were examined in the postabsorp- (13C, 99 AP) was dissolved in sterile saline solution in
tive state. After taking baseline blood and breath samples at t 5 0, an
5 ml vials, which were steam sterilized at 1218C for 15intravenous priming dose of [2H3-methyl-1-13C]methionine was given
followed by a continuous infusion for six hours. In five control subjects, minutes. Both solutions were tested for pyrogens. At
tracer infusion was discontinued after five hours as plateau was reached t 5 0, priming doses were given of 13C-bicarbonate (5.9
after 220 minutes. Blood and breath samples were taken as indicated.
mmol) and L-[2H3-methyl-1-13C]methionine (2.9 mmol ·After 120 minutes, indirect calorimetry was performed.
kg21 in the control subjects, and 3.5 mmol · kg21 in the
dialysis patients, in order to adjust for their larger homo-
cysteine pool size). Thereafter, a six-hour continuous
Infusion protocol infusion of L-[2H3-methyl-1-13C]methionine (1.8 and
2.2 mmol · kg21 · hr21 in controls and ESRD patients,All subjects were kept on a fixed diet containing 1.0 g
protein/kg body weight/day for three days prior to the respectively) was conducted with a calibrated precision
infusion pump (Teruma, Tokyo, Japan). After havingstudy. The experiments were conducted after an over-
night fast. Fasting was continued throughout the infusion assessed in the first control subject that plateau enrich-
ments were already obtained after 220 minutes, the infu-period. Only small amounts of tap water given orally
were allowed. The hemodialysis patients were studied sion period was shortened to five hours in the remaining
five healthy subjects. Plateau enrichments levels wereone day prior to a regular midweek dialysis session. All
subjects were kept in bed during the study period. At calculated as the mean of the final five 20-minute interval
samples of the infusion period.8:00 a.m., two intravenous catheters were placed in a
dorsal hand vein, one for infusion of substances and
Laboratory analysesone in the contralateral hand for sampling. Arterialized
blood samples were drawn from the dorsal hand vein For isotopic analysis of methionine, the acetyl-3,5 bis,-
trifluoromethylbenzyl derivative was prepared from 500after the hand was inserted in a heated hand box [20].
In the hemodialysis patients, blood samples were drawn ml plasma samples. Samples were purified with anion-
exchange chromatography according to Stabler et al [21].from the arterial end of the arteriovenous fistula. Blood
was collected in heparinized glass tubes, immediately The dried elutes were derivatized with acetic anhydride
(50 ml in 1 ml 1 m phosphate buffer, 408C) and 3,5 bis,-placed on ice, and centrifuged for 10 minutes at 3000
r.p.m. at 248C within 15 minutes. Plasma was stored trifluoromethylbenzylbromide (10% in acetonitrile).
The enrichments of [1-13C]methionine and [2H3-methyl-at 2308C until analyzed. Samples of end-tidal–expired
breath air were collected in a 15 ml Venojectt tube by 1-13C]methionine were measured by gas chromatography
mass spectrometry (GCMS) with negative ion chemicalinstructing the subjects to exhale through a straw. During
the last three seconds of expiration, the straw was with- ionization (with NH3) on a Hewlett-Packard (Palo Alto,
CA, USA) 5989B quadruple GCMS machine. Selecteddrawn from the tube, which was immediately closed by
the investigator. monitoring was set to 2m/z 5 190, 191, and 194 for the
acetyl-bis,trifluoromethylbenzylbromide derivative ofBefore each infusion, three baseline blood and breath
samples were collected for the determination of natural tracee (m) and tracer isotopomers ([1-13C]methionine,
m 1 1, and [2H3-methyl-1-13C]methionine, m 1 4), re-abundances of methionine isotopes and 13CO2, respec-
tively. During the infusion, blood and breath samples spectively. Enrichments (in MPE) were calculated on
the basis of the abundance relative to all measured methi-were taken at regular intervals (Fig. 1). After completion
of the protocol, the intravascular catheters were with- onine species: m 1 0, m 1 1, and m 1 4 [18, 22]. Calibra-
tion curves obtained by measurement of standard mix-drawn, and the subjects were allowed to eat.
Carbon dioxide production was measured during 30 tures containing weighed amounts of tracer and tracee
were used to correct for minor instrument variation.minutes with a ventilated hood using an indirect calorim-
eter (2900 Metabolic Measurement Cart; SensorMedics, The 13C-enrichment of carbon dioxide in breath sam-
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ples was measured on a dual-inlet isotope-ratio mass here. It thus follows that:
spectrometer (VG OPTIMA; Fisons Instruments, Mid-
Qm 5 Id 1 B 1 RM 5 S 1 TM (Eq. 3)dlewich, Cheshire, UK), against a reference gas of carbon
anddioxide, calibrated relative to PeeDee Bemelite. Isotope
abundance for 13CO2/12CO2 was measured 6 0.0001 AP Qc 5 Id 1 B 5 S 1 TS (Eq. 4)(N 5 3). The geometric mean of the three baseline breath
where Id is the tracee methionine intake via the diet (inair 13CO2 values was subtracted from each sample to
this study, Id equals zero as subjects were fasting). Bestablish a 13CO2 enrichment as AP excess (APE).
is methionine release from protein breakdown. RM isAt baseline, plasma total (that is, free and protein
homocysteine remethylation. S is methionine incorpora-bound) homocysteine was measured by high-perfor-
tion in protein synthesis. TM is methionine transmethyla-mance liquid chromatography (HPLC) with fluorescence
tion, and TS is the transsulfuration rate. Transsulfurationdetection according to the method of Ubbink, Vermaak
is calculated from the 13CO2 excretion in breath air asand Bissbort [23]. Baseline serum folate and vitamin B12
follows:levels were determined by radioassay (ICN Pharmaceuti-
cals, Costa Mesa, CA, USA) and serum pyridoxal phos- TS 5 V13CO2 * (1/[13C] methionine enrichment
phate by fluorescence HPLC. The methionine concentra- in plasma 2 1/[13C] methionine
tion in the infusate was measured in each experiment enrichment in tracer infusate) (Eq. 5)
using a standard amino acid analyzer equipped with a
in which V 13CO2 equals carbon dioxide production (inhigh-pressure analytical column packed with Utrapac 8
mmol · hr21) * breath air 13CO2 enrichment (in APE/100)resin [Biochrom 20; Pharmacia Biotech (Biochrom Ltd.),
* bicarbonate retention factor (assumed to be 0.72) [24].Cambridge, UK].
As the 13C in the carboxyl moiety is not removed dur-The MTHFR C677T polymorphism was assessed in
ing transmethylation and remethylation, equations 3 andDNA obtained from the buffy coat of ethylenediamine-
4 can be rearranged into:tetraacetic acid (EDTA) blood. The polymerase chain
reaction conditions and the sequence of the primers used RM 5 Qm 2 Qc (Eq. 6)
in the amplification of the part of the gene containing
As methionine is the only precursor of homocysteine,the mutation were taken from Frosst et al [11]. HinfI
the homocysteine disappearance (RM 1 TS) equalsrestriction enzyme analysis of the polymerase chain reac-
homocysteine appearance (TM); thus:tion products and subsequent electrophoresis in a 3%
agarose gel were used to determine the mutation status TM 5 RM 1 TS (Eq. 7)
of the subject.
Methionine and homocysteine rates (in mmol · hr21) were
Calculations expressed per kg body weight.
With the primed, continuous infusion of [2H3-methyl- Statistical analysis1-13C]methionine, methionine transmethylation, and
The plateau isotopic enrichment levels were analyzedhomocysteine transsulfuration and remethylation can be
by visual inspection and analysis of variance. Valuesestimated from calculations at steady state, according to
are expressed as mean 6 sem unless otherwise stated.the model described by Storch et al [18]. The major
Differences between patients and controls were com-features of the model are summarized in this article.
pared with unpaired Student t-tests and Mann-WhitneyFrom the enrichments of methionine (m 1 4 and m 1
tests as appropriate. Correlation coefficients were calcu-1), the whole body methionine-methyl rate of appear-
lated with Pearson’s and Spearman’s tests as appropriate.ance and disappearance (Qm) and methionine-carboxyl
To analyze sex, age, vitamin status, and uremia as possi-rate of appearance and disappearance (Qc) are calculated
ble determinants of the various flux rates, multivariateas follows:
regression was performed in the total group after adding
Qm 5 I * (Etr/E4 2 1) (Eq. 1) a factor “ESRD present (0) or absent (1)” to the model.
A P value , 0.05 was accepted as the level of significance.Qc 5 I * (Etr/(E1 1 E4) 2 1) (Eq. 2)
where I is the tracer infusion rate (in mmol · hr21), Etr
RESULTSthe enrichment of the tracer in the infusate (m 1 4, 95
MPE), and E1 and E4 are the plasma plateau enrichments Plateau plasma methionine and breath air 13CO2 en-
richments were obtained in all individuals (analysis ofof [1-13C]methionine (m 1 1) and [2H3-methyl-1-
13C]methionine (m 1 4), respectively. variance, P , 0.05) with a mean of coefficient of variation
of 7% (N 5 5 samples). In the ESRD patients, the pla-In the steady state, the sum of inputs equals the sum
of outputs for various components, as described earlier teau was reached after 260 minutes and, in the control
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Table 2. Rates of methionine and homocysteine metabolism in ESRD patients and control subjects in the postabsorptive state
Qm Qc RM TS TM B S
Subject mmol · kg21 · hr21
ESRD
#1 18.4 16.3 2.1 1.7 3.9 16.3 14.5
#2 17.6 14.8 2.8 3.0 5.8 14.8 11.8
#3 18.3 15.7 2.6 3.0 5.6 15.7 12.6
#4 23.1 20.2 2.9 2.4 5.3 20.2 17.8
Mean 6 sem 19.461.3 16.861.2 2.660.2 2.560.3 5.260.4 16.861.2 14.261.3
Control
#1 22.3 18.3 4.0 3.2 7.2 18.3 15.1
#2 22.6 17.4 5.2 3.0 8.2 17.4 14.4
#3 23.8 19.9 3.9 2.8 6.7 19.9 17.2
#4 20.4 17.4 3.0 3.2 6.2 17.4 14.2
#5 21.0 18.0 3.1 3.0 6.0 18.0 15.0
#6 20.1 16.7 3.3 2.8 6.2 16.7 13.9
Mean 6 sem 21.760.6 18.060.5 3.860.3 3.060.1 6.860.3 18.060.5 15.060.5
P 0.09 0.31 0.03 0.11 0.02 0.31 0.53
Abbreviations are: Qm, methionine methylflux; Qc, methionine carboxylflux; RM, remethylation; TS, transsulfuration; TM, transmethylation; B, methionine from
protein breakdown; S, methionine to protein synthesis.
subjects, after 220 minutes. Conditions for mass spec-
trometry measurements were similar in both groups
(isotopic enrichment ranged between 1 to 2 MPE for
[1-13C]methionine, between 5 to 10 MPE for [2H3-methyl-
1-13C]methionine, and breath air 13CO2 was .0.0020 APE
in each subject). The carbon dioxide production was
similar in patients and controls (ESRD, 2.60 6 0.33;
controls, 2.61 6 0.09 ml · kg21 · min21, P 5 0.97).
Results for conversion rates in the methionine-homo-
cysteine cycle calculated from the tracer study are pre-
sented in Table 2. Remethylation and transmethylation
were both significantly decreased in the ESRD group,
whereas transsulfuration, protein synthesis, and break-
down were not significantly different. Figure 2 depicts
the individual results for remethylation and transmethyl-
ation in both groups. Remethylation and transmethyla-
tion rates were highly correlated when data from both
groups were pooled (r 5 0.95, P , 0.001). The transsul-
furation rate also showed a significant correlation with
transmethylation (r 5 0.74, P 5 0.01), but no significant
correlation with remethylation. Fig. 2. Individual values of remethylation rates plotted against trans-
methylation rates. The regression line with its 95% confidence intervalHyperhomocysteinemia was present in all ESRD pa-
is given for the total group. Symbols are: (h) control subjects; (d)tients, whereas the control subjects had plasma total hemodialysis patients.
homocysteine levels within the reference range (that is,
#15 mmol/liter). Serum folate, vitamin B12 and vitamin
B6 levels were similar in both groups. None of the dialysis
DISCUSSIONpatients were homozygous for the MTHFR C677→T
mutation. Multivariate analysis showed that lower re- The results of this investigation are the first data on
in vivo rates of methionine and homocysteine metabo-methylation and transmethylation were significantly re-
lated to being an ESRD patient (standardized r 5 0.68, lism in patients with renal disease. At increased concen-
trations of total homocysteine in plasma of these pa-P 5 0.03, and standardized r 5 0.72, P 5 0.02, respec-
tively), but not to any of the B vitamins, sex, or age. tients, the homocysteine transsulfuration appeared not
to be affected when compared with apparently healthyThe only significant determinant of transsulfuration was
serum vitamin B6 (standardized r 5 0.64, P 5 0.045). control subjects. In contrast, the methionine transmeth-
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ylation and the homocysteine remethylation were pro- steady-state conditions. Guttormsen et al studied bio-
availability and distribution volume by oral and intrave-portionally decreased. In the healthy control subjects,
the calculated postabsorptive rates of homocysteine re- nous homocysteine (and not methionine) loading [12].
They found that folic acid therapy did not normalizemethylation, homocysteine transsulfuration, and methio-
nine transmethylation were virtually identical to those total body homocysteine clearance after homocysteine
loading. These findings do not necessarily contradict ourreported by the group of Young et al applying the same
isotope model and at similar dietary nitrogen intake of data. In addition to an impaired homocysteine remethyl-
ation, which is best detected in the fasting steady state,1.0 g · kg21 · day21 [25].
In patients with ESRD, only a nonsignificant trend renal failure patients may have a transsulfuration defect
on homocysteine or methionine loading as well. Such awas observed toward lower rates of homocysteine trans-
sulfuration compared with healthy control subjects. A defect is not likely to be responsive to folate therapy.
On theoretical grounds, elevated fasting transmethyla-closer analysis of the data in Table 2 shows that this
trend is mainly due to the very low rate of homocysteine tion could be postulated as a cause of hyperhomocys-
teinemia. When fasting transsulfuration is unchanged,transsulfuration measured in patient 1. This patient also
had the lowest vitamin B6 concentration (11 nmol · l21). remethylation would be elevated as well as a conse-
quence. Our observations point to the opposite. Trans-Because in the whole group of subjects serum vitamin
B6 was found to be a determinant of homocysteine trans- methylation is decreased, which is a counter-intuitive
finding as less supply is an unlikely explanation for ele-sulfuration in the multivariate analysis, the tendency to-
ward a lower rate of homocysteine transsulfuration in vated plasma homocysteine levels. However, remethyla-
tion is also decreased and evidently more impaired thanthe ESRD patients may be related to their tendency of
having a lower serum vitamin B6 concentration. In that the consequential decrease in transmethylation.
Several factors may be implicated in the decreasedcase, it can be concluded that ESRD per se does not
affect the homocysteine transsulfuration. Irrespective of homocysteine remethylation in ESRD. The most obvi-
ous cause is a low folate and/or vitamin B12 status, butthe level of total homocysteine in plasma in patients with
ESRD, a significant and proportional decrease in the this was not the case in our patients. Alternative distur-
bances in folate metabolism that have been describedmethionine transmethylation and homocysteine remeth-
ylation was observed. A remarkable finding was that the in ESRD patients include an impaired transmembrane
transport of folic acid [26] and a decreased activity ofpatient with polycystic kidney disease had the lowest
remethylation and also the lowest plasma homocysteine, plasma folate conjugase, an enzyme that splits polygluta-
mate forms of folate into biologically more active oligo-which could indicate that patients with polycystic kidney
disease constitute a different patient population. This glutamates and monoglutamates [27]. Further evidence
for a disturbed folate metabolism is provided by inter-issue requires further investigation. Nevertheless, the re-
sults of this study indicate that an impaired whole body vention studies that show that only folic acid-containing
regimens are able to lower, but not normalize, plasmaremethylation of homocysteine, and not its transsulfura-
tion, is a plausible cause of hyperhomocysteinemia in homocysteine levels in renal failure patients [3–9]. It
remains to be elucidated whether the homocysteine re-hemodialysis patients. This may seem a somewhat unex-
pected finding, particularly in view of the data of Guttor- methylation rate in ESRD patients remains decreased
during folic acid treatment. In addition, it can not bemsen et al [12]. They observed a significantly decreased
clearance of total homocysteine from plasma in patients excluded that the concentration or the activity of the
enzymes involved in homocysteine remethylation are al-with chronic renal failure. The decreased clearance could
not be influenced by the administration of folic acid. tered in ESRD. Homozygosity for the thermolabile
MTHFR variant has a similar frequency of approxi-They concluded that the decreased clearance in patients
with renal failure could not be due a defect in homocys- mately 10 to 15% in ESRD patients and in control sub-
jects [28, 29], which makes this enzyme a priori an un-teine remethylation and speculated that the decreased
clearance of total homocysteine was brought about by likely candidate to explain the 85 to 100% prevalence of
hyperhomocysteinemia in ESRD. As none of the dialysisdecreased renal extraction of homocysteine. This specu-
lation was based on findings in postabsorptive rats, show- patients in our study were homozygous for the C677→T
mutation, the decreased homocysteine remethylationing net renal extraction an subsequent renal transsulfura-
tion of homocysteine [15, 16]. We have, however, could evidently not be explained by the thermolabile
MTHFR enzyme variant. Also, abnormalities in the be-recently shown that such a mechanism is not of impor-
tance in humans, because no net renal extraction of taine-dependent remethylation pathway do not offer a
plausible explanation, as betaine, when added to folichomocysteine was observed in fasting humans [17]. It
should be stressed that the findings in this study are true acid, does not further lower plasma homocysteine in
hemodialysis patients [3]. Finally, regulatory factors inunder the assumption that body compartments are in
complete equilibrium and that they pertain to fasting methionine-homocysteine metabolism may be altered in
van Guldener et al: Homocysteine and methionine metabolism in ESRD1070
ESRD. It has been proposed that a high AdoMet level REFERENCES
decreases remethylation by inhibiting betaine homocys- 1. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL,
Jacobsen DW, Robinson K, Dennis VW: Prospective study ofteine transferase and MTHFR [10]. High AdoHcy levels
hyperhomocysteinemia as an adverse cardiovascular risk factor inrelative to AdoMet are thought to inhibit transmethyla-
end-stage renal disease. Circulation 97:138–141, 1998
tion reactions [30]. Recent research indicates that the 2. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D,
Green R, Vigo P, Mayer EL, Selhub J, Kutner M, JacobsenAdoMet/AdoHcy ratio is decreased in erythrocytes [31]
DW: Hyperhomocysteinemia confers an independent increasedand plasma [32] of dialysis patients, especially as the risk of atherosclerosis in end-stage renal disease and is closely
result of elevated AdoHcy levels. A low AdoMet/AdoHcy linked to plasma folate and pyridoxine concentrations. Circulation
94:2743–2748, 1996ratio could be responsible for our observation of a de-
3. van Guldener C, Janssen MJFM, Lambert J, ter Wee PM, Jakobs
creased transmethylation rate, but is unlikely that the C, Donker AJM, Stehouwer CDA: No change in impaired endo-
thelial function after long-term folic acid therapy of hyperhomocys-latter would cause hyperhomocysteinemia because it has
teinaemia in haemodialysis patients. Nephrol Dial Transplantbeen made plausible that the high erythrocyte AdoHcy
13:106–112, 1998
levels are the result and not the cause of high plasma 4. Wilcken DEL, Gupta VJ, Betts AK: Homocysteine in the plasma
of renal transplant recipients: Effects of cofactors for methioninehomocysteine levels [33]. Decreased transmethylation
metabolism. Clin Sci 61:743–749, 1981resulting from elevated AdoHcy levels has been associ- 5. Arnadottir M, Brattstro¨m L, Simonsen O, Thysell H, Hultberg
ated with impaired erythrocyte membrane protein repair B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyri-
doxine and folic acid supplementation on serum lipid and plasma[31] and has also been proposed as a mechanism for
homocysteine concentrations in dialysis patients. Clin Nephrol
other cellular abnormalities in chronic renal failure [34]. 40:236–240, 1993
6. Janssen MJFM, van Guldener C, de Jong GMT, van den BergIn this study, we indeed observed a significant decrease
M, Stehouwer CDA, Donker AJM: Folic acid treatment of hyper-in transmethylation of methionine, but AdoMet and
homocysteinemia in dialysis patients. Miner Electrolyte Metab
AdoHcy concentrations were not determined. This topic 22:110–114, 1996
7. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Na-remains a subject for future research.
deau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-In conclusion, this study with [2H3-methyl-1-13C]methi- vitamin treatment of hyperhomocysteinemia in dialysis patients.
onine shows that in hemodialysis patients with hyperho- Kidney Int 49:147–152, 1996
8. Perna AF, Ingrosso D, Desanto NG, Galletti P, Brunone M,mocysteinemia, whole body homocysteine remethylation
Zappia V: Metabolic consequences of folate-induced reduction of
and methionine transmethylation are proportionally de- hyperhomocysteinemia in uremia. J Am Soc Nephrol 8:1899–1905,
1997creased as compared with healthy control subjects. In
9. van Guldener C, Janssen MJFM, Lambert J, ter Wee PM,contrast, whole body homocysteine transsulfuration ap-
Donker AJM, Stehouwer CDA: Folic acid treatment of hyperho-
peared to be unaffected when corrected for variation in mocysteinemia in peritoneal dialysis patients: No change in endo-
thelial function after long-term therapy. Perit Dial Int 18:282–289,the vitamin B6 status. Decreased homocysteine remethyl-
1998ation is a good candidate to explain hyperhomocysteine- 10. Finkelstein JD: Methionine metabolism in mammals. J Nutr Bio-
mia in hemodialysis patients. chem 1:228–237, 1990
11. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews
RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van den Heu-
ACKNOWLEDGMENTS vel LP, Rozen R: A candidate genetic risk factor for vascular
disease: A common mutation in methylenetetrahydrofolate reduc-
This study was supported by the Dutch Kidney Foundation, grant tase. Nat Genet 10:111–113, 1995
number C 98-1706. Dr. Stehouwer is supported by a Clinical Research 12. Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic
Fellowship from the Diabetes Fonds Nederland and the Dutch Organi- basis of hyperhomocysteinemia in patients with chronic renal fail-
zation for Scientific Research (NWO). ure. Kidney Int 52:495–502, 1997
13. Refsum H, Helland S, Ueland PM: Radioenzymic determination
of homocysteine in plasma and urine. Clin Chem 31:624–628, 1985Reprint requests to Coen van Guldener, M.D., Department of Internal
14. Stabler SP, Marcell PD, Podell ER, Allen RH: QuantitationMedicine, University Hospital Vrije Universiteit, P.O. Box 7057, 1007
of total homocysteine, total cysteine, and methionine in normalMB Amsterdam, The Netherlands.
serum and urine using capillary gas chromatography-mass spec-E-mail: c.vanguldener@azvu.nl
trometry. Anal Biochem 162:185–196, 1987
15. House JD, Brosnan ME, Brosnan JT: Characterization of homo-
cysteine metabolism in the rat kidney. Biochem J 328:287–292,
APPENDIX 1997
16. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J: Net
Abbreviations used in this article are: AdoHcy, S-adenosylhomo- uptake of plasma homocysteine by the rat kidney in vivo. Athero-
cysteine; ADPKD, autosomal dominant polycystic kidney disease; sclerosis 116:59–62, 1995
AdoMet, S-adenosylmethionine; AP, atom percent; APE, atom per- 17. van Guldener C, Donker AJM, Jakobs C, Teerlink T, de Meer
cent excess; B, methionine from protein breakdown; CGN, chronic K, Stehouwer CDA: No net renal extraction of homocysteine in
glomerulonephritis; ESRD, end-stage renal disease; GCMS, gas chro- fasting humans. Kidney Int 54:166–169, 1998
matography mass spectrometry; HUS, hemolytic uremic syndrome; 18. Storch KJ, Wagner DA, Burke JF, Young VR: Quantitative
MPE, mole percent excess; MTHFR, 5,10-methylenetetrahydrofolate study in vivo of methionine cycle in humans using [methyl-2H3]-
reductase; PCR, polymerase chain reaction; Qc, methionine carboxyl- and [1-13C] methionine. Am J Physiol 255:E322–E331, 1988
flux; Qm, methionine methylflux; R, remethylation; S, methionine to 19. Matthews DE, Schwarz HP, Yang RD, Motil KJ, Young VR,
protein synthesis; tHcy, plasma total homocysteine; TM, transmethyla- Bier DM: Relationship of plasma leucine and a-ketoisocaproate
during a L-[1-13C]leucine infusion in man: A method for measuringtion; TS, transsulfuration.
van Guldener et al: Homocysteine and methionine metabolism in ESRD 1071
human intracellular tracer enrichment. Metabolism 31:1105–1112, 28. Fo¨dinger M, Mannhalter C, Wo¨lfl G, Pabinger I, Mu¨ller E,
1982 Schmid R, Ho¨rl WH, Sunder-Plassmann G: Mutation (677 C to
20. McGuire EAH, Helderman JH, Tobin JD, Andres R, Berman T) in the methylenetetrahydrofolate reductase gene aggravates
M: Effects of arterial versus venous sampling on analysis of glucose hyperhomocysteinemia in hemodialysis patients. Kidney Int
kinetics in man. J Appl Physiol 41:565–573, 1976 52:517–523, 1997
21. Stabler SP, Lindenbaum J, Savage DG, Allen RH: Elevation 29. Vychytil A, Fo¨dinger M, Wo¨lfl G, Enzenberger B, Auinger
of serum cystathionine levels in patients with cobalamin and folate M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Ho¨rl
deficiency. Blood 81:3404–3413, 1993 WH, Sunder-Plassmann G: Major determinants of hyperhomo-
22. Matthews DE, Motil KJ, Rohrbaugh DK, Burke JF, Young cysteinemia in peritoneal dialysis patients. Kidney Int 53:1775–
VR, Bier DM: Measurement of leucine metabolism in man from 1782, 1998
a primed, continuous infusion of L-[1-13C]leucine. Am J Physiol 30. McKeever M, Molloy A, Weir DG, Young PB, Kennedy DG,
238:E473–E479, 1980 Kennedy S, Scott JM: An abnormal methylation ratio induces
23. Ubbink JB, Vermaak WJH, Bissbort S: Rapid high-performance hypomethylation in vitro in the brain of pig and man, but not in
liquid chromatographic assay for total homocysteine levels in hu- rat. Clin Sci 88:73–79, 1995
man serum. J Chromatogr 565:441–446, 1991 31. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De
24. Hoerr RA, Yu YM, Wagner DA, Burke JF, Young VR: Recov- Santo NG: Enzymatic methyl esterification of erythrocyte mem-
ery of 13C in breath from NaH13CO3 infused by gut and vein: Effect brane proteins is impaired in chronic renal failure. J Clin Investof feeding. Am J Physiol 257:E426–E438, 1989
91:2497–2503, 199325. Young VR, Wagner DA, Burini R, Storch KJ: Methionine kinet-
32. Loehrer FMT, Angst CP, Brunner FP, Haefeli WE, Fowlerics and balance at the 1985 FAO/WHO/UNU intake requirement
B: Evidence for S-adenosylmethionine: S-adenosylhomocysteinein adult men studied with L-[2H3-methyl-1-13C]methionine as a
ration in patients with end-stage renal failure: A cause for disturbedtracer. Am J Clin Nutr 54:377–385, 1991
methylation reactions? Nephrol Dial Transplant 13:656–661, 199826. Jennette JC, Goldman ID: Inhibition of the membrane transport
33. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V:of folates by anions retained in uremia. J Lab Clin Med 86:834–843,
Mechanism of erythrocyte accumulation of methylation inhibitor1975
S-adenosylhomocysteine in uremia. Kidney Int 47:247–253, 199527. Livant EJ, Tamura T, Johnston KE, Vaughn WH, Bergman SM,
34. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG:Forehand J, Walthaw J: Plasma folate conjugase activities and
Membrane protein damage and methylation reactions in chronicfolate concentrations in patients receiving hemodialysis. J Nutr
Biochem 5:504–508, 1994 renal failure. Kidney Int 50:358–366, 1996
